IL150510A0 - Transduction of recombinases for inducible gene targeting - Google Patents

Transduction of recombinases for inducible gene targeting

Info

Publication number
IL150510A0
IL150510A0 IL15051001A IL15051001A IL150510A0 IL 150510 A0 IL150510 A0 IL 150510A0 IL 15051001 A IL15051001 A IL 15051001A IL 15051001 A IL15051001 A IL 15051001A IL 150510 A0 IL150510 A0 IL 150510A0
Authority
IL
Israel
Prior art keywords
recombinases
transduction
gene targeting
inducible gene
inducible
Prior art date
Application number
IL15051001A
Original Assignee
Artemis Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00100351A external-priority patent/EP1118668A1/en
Application filed by Artemis Pharmaceuticals Gmbh filed Critical Artemis Pharmaceuticals Gmbh
Publication of IL150510A0 publication Critical patent/IL150510A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15051001A 2000-01-07 2001-01-05 Transduction of recombinases for inducible gene targeting IL150510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00100351A EP1118668A1 (en) 2000-01-07 2000-01-07 Transduction of recombinases for inducible gene targeting
EP00124595 2000-11-10
PCT/EP2001/000060 WO2001049832A2 (en) 2000-01-07 2001-01-05 Transduction of recombinases for inducible gene targeting

Publications (1)

Publication Number Publication Date
IL150510A0 true IL150510A0 (en) 2003-02-12

Family

ID=26070411

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15051001A IL150510A0 (en) 2000-01-07 2001-01-05 Transduction of recombinases for inducible gene targeting

Country Status (6)

Country Link
EP (1) EP1244796A2 (en)
JP (1) JP2003518947A (en)
AU (1) AU3368301A (en)
CA (1) CA2396149A1 (en)
IL (1) IL150510A0 (en)
WO (1) WO2001049832A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU2003208876A1 (en) * 2002-02-21 2003-09-09 Vision 7 Gmbh Methods for conducting site-specific dna recombination
WO2003076561A2 (en) * 2002-03-09 2003-09-18 Artemis Pharmaceuticals Gmbh Recombinase fusion protein with enhanced cellular uptake
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
CN100410369C (en) * 2006-06-22 2008-08-13 复旦大学 Fi-C31 integrase modified TAT and NLS polypeptide and its use
JP5631595B2 (en) 2007-03-02 2014-11-26 ノノ インコーポレイテッド Methods for treating stroke and other diseases without inhibiting N-type calcium channels
EP2268821A1 (en) * 2008-04-25 2011-01-05 New York Blood Center, Inc. Abi1/hssh3bp1 conditional knockout mouse
EP2527448A1 (en) 2011-05-23 2012-11-28 Novozymes A/S Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE173016T1 (en) * 1992-08-21 1998-11-15 Biogen Inc TRANSPORT POLYPEPTIDES DERIVED FROM TAT
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
AU3266899A (en) * 1998-03-06 1999-09-20 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
CA2330560A1 (en) * 1998-04-28 1999-11-04 Washington University Methods for transducing fusion molecules
GB9810423D0 (en) * 1998-05-15 1998-07-15 Cancer Res Campaign Tech Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU4342900A (en) * 1999-04-12 2000-11-14 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy

Also Published As

Publication number Publication date
JP2003518947A (en) 2003-06-17
WO2001049832A3 (en) 2002-02-21
CA2396149A1 (en) 2001-07-12
WO2001049832A2 (en) 2001-07-12
AU3368301A (en) 2001-07-16
EP1244796A2 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
AU2001265187A1 (en) Chimeric viral vectors for gene therapy
HUP0103571A3 (en) Characterisation of gene function using double stranded rna inhibition
AU2001291656A1 (en) Gene silencing vector
AU2002219841A1 (en) Vectors for conditional gene inactivation
ATE317007T1 (en) GENES OF THE 1-DESOXY-D-XYLULOSE BIOSYNTHESIS PATHWAY
AU2001280701A1 (en) Nucleic acids compositions conferring dwarfing phenotype
AU4430701A (en) Compounds for targeting
AU4728501A (en) Gene targeting method
AU2001266225A1 (en) Decondensation of dna
IL150510A0 (en) Transduction of recombinases for inducible gene targeting
AU2001250428A1 (en) Genes of the 1-desoxy-d-xylulose biosynthesis path
IL149599A0 (en) Use of disease-associated gene
AU6424701A (en) Gasc1 gene
AU2002360394A1 (en) Facilitation of rna interference
AU2001282894A1 (en) Transgenic mice containing targeted gene disruptions
AU2002307393A1 (en) Inducible expression of transfected genes
IL151759A0 (en) Transgenic mice containing targeted gene disruptions
AU2002217989A1 (en) Transgenic mice containing targeted gene disruptions
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
AU2002219992A1 (en) Targeted regulation of gene expression
AU2001258659A1 (en) Improved methods of transfection
AU2002239539A1 (en) Transgenic mice containing targeted gene disruptions
GB0005856D0 (en) Genetic constructs
EP1296138A4 (en) Use of disease-associated gene
AU2001245942A1 (en) Establishment of cellular manipulations which enhance oligo-mediated gene targeting